Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma

Shigeo Godo, Yoshitaro Yoshida, Naoki Kawamorita, Koji Mitsuzuka, Yu Kawazoe, Motoo Fujita, Daisuke Kudo, Ryosuke Nomura, Hiroaki Shimokawa, Shigeki Kushimoto

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia. An abundance of caution for unusual and unpredictable toxicities is warranted when using axitinib.

本文言語English
ページ(範囲)2895-2900
ページ数6
ジャーナルInternal Medicine
57
19
DOI
出版ステータスPublished - 2018

ASJC Scopus subject areas

  • 内科学

フィンガープリント

「Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル